Cargando…

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many biological processes. Deregulated FGFR signaling plays an important role in tumor development and progression in different cancer types. FGFR genomic alterations, including FGFR gene fusions that originate by c...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Antonella, Esposito Abate, Riziero, Rachiglio, Anna Maria, Maiello, Monica Rosaria, Esposito, Claudia, Schettino, Clorinda, Izzo, Francesco, Nasti, Guglielmo, Normanno, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555921/ https://www.ncbi.nlm.nih.gov/pubmed/32962091 http://dx.doi.org/10.3390/ijms21186856

Ejemplares similares

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine
por: Dotolo, Serena, et al.
Publicado: (2021)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2020)

Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice
por: Dotolo, Serena, et al.
Publicado: (2022)

Challenges in bioinformatics approaches to tumor mutation burden analysis
por: Fenizia, Francesca, et al.
Publicado: (2021)

Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022)

External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology
por: Roma, Cristin, et al.
Publicado: (2013)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors
por: Normanno, Nicola, et al.
Publicado: (2023)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
por: Damato, Angela, et al.
Publicado: (2020)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions
por: Tamura, Ryo, et al.
Publicado: (2018)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
por: Sridharan, Vishwajith, et al.
Publicado: (2022)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
por: Esposito Abate, Riziero, et al.
Publicado: (2019)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases
por: Ballester, Leomar Y., et al.
Publicado: (2019)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel
por: Scarpa, Aldo, et al.
Publicado: (2013)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

I BET on anti‐FGFR to fight cancer resistance
por: Benedetti, Rosaria, et al.
Publicado: (2019)

Identification and targeting of an FGFR fusion in a pediatric thalamic “central oligodendroglioma”
por: Linzey, Joseph R., et al.
Publicado: (2017)

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium
por: Best, Sarah A., et al.
Publicado: (2018)

FGFR3-TACC3 fusion in solid tumors: mini review
por: Costa, Ricardo, et al.
Publicado: (2016)

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
por: Kongpetch, Sarinya, et al.
Publicado: (2020)

Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
por: Nita, Alexandru, et al.
Publicado: (2021)

FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma
por: Gött, Hanna, et al.
Publicado: (2022)

The Aberrant Expression of the Mesenchymal Variant of FGFR2 in the Epithelial Context Inhibits Autophagy
por: Nanni, Monica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mplmddvr752iot89cqap9jllqr